Dr. Laura Lambrecht | Oncology Pharmaceuticals | Best Researcher Award
Licenced Physician with a doctoral degree (MD) at Department of Medicine V, University Hospital, LMU Munich | Germany
Dr. med. Laura Lambrecht, born in Munich, is a dedicated physician specializing in pneumology and cardiology with a strong research background in experimental adult cardiology. She completed her medical studies at Ludwig-Maximilians-Universität München and the Technical University of Munich, earning her approbation as a physician. Her doctoral research at the Deutsches Herzzentrum München focused on the functional impact of acetylsalicylic acid on platelet function in carriers of genetic variants in the GUCY1A1 gene, associated with coronary heart disease risk. She actively contributes to clinical work, academic research, and professional leadership roles, while also engaging in cultural and educational initiatives.
Publication Profile
Orcid
Education
Dr. Laura Lambrecht earned her Allgemeine Hochschulreife from Max-Bon-Gymnasium Germering with top marks. She began her pre-clinical medical studies at Ludwig-Maximilians-Universität München, achieving “gut” in her first medical examination. She continued her clinical medical studies at the Technical University of Munich, also earning “gut,” and successfully passed her second and third medical examinations. She obtained her approbation as a physician in December. Her doctoral work at the Deutsches Herzzentrum München investigated the effects of acetylsalicylic acid on platelet function in genetically predisposed individuals. She holds certifications in Good Clinical Practice (GCP) and is a member of the Young-DZHK research network.
Experience
Dr. Lambrecht is currently a physician in training for pneumology at the LMU Klinikum, with a prior rotation in cardiology at the same institution. She has also served as a cardiology trainee at the Medizinisches Versorgungszentrum Dachau, a teaching practice of LMU Munich. Her research experience includes experimental adult cardiology at the Deutsches Herzzentrum München in the group of Prof. Dr. H. Schunkert. She has held leadership roles such as assistant representative at the LMU Klinikum. Alongside her clinical career, she has been actively involved in student representation, faculty governance, and medical community engagement through various institutional committees and organizations.
Awards and Honors
Dr. Lambrecht’s academic achievements include graduating from Max-Bon-Gymnasium Germering with “sehr gut” and consistently strong performance in her medical studies at LMU and TU Munich. She earned her approbation as a physician and secured a place in the prestigious Young-DZHK network, reflecting her recognized potential in cardiovascular research. She received funding for her doctoral project examining the genetic and pharmacological interplay in coronary heart disease. Her leadership as assistant representative and elected student council member also reflects peer recognition. Her commitment to academic excellence, research innovation, and community service positions her as a promising contributor to both clinical and research fields.
Research Focus
Dr. Lambrecht’s primary research interest lies in cardiovascular pharmacogenetics, particularly the influence of genetic variants on drug response. Her doctoral project focused on the functional effects of acetylsalicylic acid on platelet function in carriers of genetic variants in the coronary heart disease risk gene GUCY1A1. She is interested in translating molecular findings into personalized therapeutic strategies for cardiovascular patients. Her work integrates clinical cardiology with laboratory-based functional assays to better understand genotype-specific treatment responses. Additionally, she engages in interdisciplinary collaboration between cardiology and pneumology, aiming to address comorbid conditions and improve patient care through evidence-based, precision medicine approaches.
Publication Top Notes
Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.
Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation.